The search for nucleoside/nucleotide analog inhibitors of dengue virus

Yen Liang Chen, Fumiaki Yokokawa, Pei-Yong Shi

Research output: Contribution to journalArticle

36 Scopus citations

Abstract

Abstract Nucleoside analogs represent the largest class of antiviral agents and have been actively pursued for potential therapy of dengue virus (DENV) infection. Early success in the treatment of human immunodeficiency virus (HIV) infection and the recent approval of sofosbuvir for chronic hepatitis C have provided proof of concept for this class of compounds in clinics. Here we review (i) nucleoside analogs with known anti-DENV activity; (ii) challenges of the nucleoside antiviral approach for dengue; and (iii) potential strategies to overcome these challenges. This article forms part of a symposium in Antiviral Research on flavivirus drug discovery.

Original languageEnglish (US)
Article number3670
Pages (from-to)12-19
Number of pages8
JournalAntiviral Research
Volume122
DOIs
StatePublished - Aug 10 2015
Externally publishedYes

    Fingerprint

Keywords

  • Antiviral therapy
  • Dengue virus
  • Monophosphate prodrug
  • Nucleoside analogs

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this